azacitidine + PD-1

Azacitidine + PD-1 is an investigational combination therapy consisting of the hypomethylating agent azacitidine and an unspecified PD-1 immune checkpoint inhibitor. Azacitidine is a small molecule that inhibits DNA methyltransferase (DNMT), leading to DNA demethylation and the re-expression of silenced genes, which can sensitize tumor cells to immune attack and modulate the tumor microenvironment. The PD-1 inhibitor component is a monoclonal antibody that blocks the interaction between the Programmed Death-1 (PD-1) receptor on T-cells and its ligands (PD-L1 and PD-L2), thereby restoring the anti-tumor activity of exhausted T-cells. This combination is being evaluated in Phase 2 clinical trials (notably NCT06190067) for the treatment of relapsed or refractory classic Hodgkin lymphoma (cHL), aiming to overcome resistance to checkpoint inhibition through epigenetic priming.

Other names

azacitidine plus PD-1 therapy